HB Fuller Director R. Jeffrey Bailly Files Form 4 for September 30
HB Fuller Company director R. Jeffrey Bailly filed a Form 4 regulatory disclosure for insider transactions ending September 30.
6 articles
HB Fuller Company director R. Jeffrey Bailly filed a Form 4 regulatory disclosure for insider transactions ending September 30.
H.B. Fuller Director R. Jeffrey Bailly purchased $500,000 in shares near the 52-week low. The company reported mixed Q3 2026 earnings with EPS beating expectations but revenue falling short.
H.B. Fuller director R. Jeffrey Bailly bought 10,000 shares at $50 each through a trust on October 7, 2026, according to SEC filings. The move signals positive insider sentiment for the adhesive and c
HB Fuller Company director R. Jeffrey Bailly received 1,300 restricted stock units on September 30, 2026, converting to common stock with an expiration date of September 30, 2029.
H.B. Fuller appointed R. Jeffrey Bailly to its board to enhance medical technology expertise, aligning with a focus on higher-margin healthcare exposure while facing activist investor pressure for a s
H.B. Fuller appointed R. Jeffrey Bailly to its Board of Directors to leverage his manufacturing and medical technology expertise. The appointment supports the company's strategic shift toward higher-m